- Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
-
Carvalho FL, Zeymo A, Egan J, Kelly CH, Zheng C, Lynch JH, Hwang J, Stamatakis L, Krasnow RE, Kowalczyk KJ
- KMID: 2503548
- Investig Clin Urol.
- 2020 Jul;61(4):390-396.
- doi: 10.4111/icu.2020.61.4.390
Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard of care for muscleinvasive bladder cancer (MIBC). However, NAC is used in less than 20% of patients with... -
- CITED
-
- Close
- SHARE
-
- Close
